EC
MRNA icon

EntryPoint Capital’s Moderna MRNA Stock Holding History

EntryPoint Capital’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6,917
Closed -$351K – 896
2026
Q1 		$351K Sell
6,917
-10,521
-60% -$491K 0.1% 401
2025
Q4 		$514K Buy
17,438
+8,794
+102% +$239K 0.2% 154
2025
Q3 		$223K Buy
8,644
+672
+8% +$18.7K 0.09% 505
2025
Q2 		$220K Sell
7,972
-307
-4% -$8.09K 0.11% 437
2025
Q1 		$235K Buy
+8,279
New +$294K 0.11% 458
2024
Q1 		– Sell
-552
Closed -$54.9K – 1633
2023
Q4 		$54.9K Buy
+552
New +$46.4K 0.05% 673

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

EntryPoint Capital's MRNA Position: Q2 2026 in Review

EntryPoint Capital sold out of Moderna (MRNA) in Q2 2026, closing a stake of 6,917 shares — an estimated $351K sold.

EntryPoint Capital first reported a position in MRNA in Q4 2023 and held it in 6 quarters. The position peaked at $514K in Q4 2025. 775 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • EntryPoint Capital reported no remaining Moderna position as of Q2 2026 after selling out during the quarter.
  • EntryPoint Capital sold 6,917 Moderna shares in Q2 2026, an estimated $351K.
  • EntryPoint Capital first reported a position in Moderna in Q4 2023 and held it in 6 quarters.
  • EntryPoint Capital's Moderna position peaked at $514K in Q4 2025.
  • 775 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.